aibio
Listings ·
Scinai Immunotherapeutics regains Nasdaq bid price compliance
Nasdaq's September 18, 2026 letter says the ADSs closed at $1.00 or more for 19 consecutive business days. The matter is closed.
SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics (SCNI) news SCNI offering news
Latest Scinai Immunotherapeutics news
- Financings
Scinai Immunotherapeutics raises $1.38 million through Yorkville equity line drawdowns
The sales were priced at about $3.03 per ADS, a 3% discount to market. Scinai also says a cost-cutting program will lower annual employment costs by about $815,000.
- Distress
Scinai files late 20-F notice over accounting for $29 million loan conversion
The company cites the conversion of its European Investment Bank debt to preferred equity and personnel losses after year-end, and expects to file by May 15, 2025.
Scinai Immunotherapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $1.3 million | $658,000 |
| Research and development | $2.4 million | $5.5 million |
| Net income (loss) | -$8.3 million | $4.8 million |
| Cash from operations | -$6.0 million | -$6.3 million |
| Cash and equivalents | $1.7 million | $2.0 million |
Questions about Scinai Immunotherapeutics
Has Scinai Immunotherapeutics raised money recently?
Our latest story on this, dated Jun 12, 2025: "Scinai Immunotherapeutics raises $1.38 million through Yorkville equity line drawdowns". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Scinai Immunotherapeutics?
Scinai Immunotherapeutics Ltd. trades under the ticker SCNI on NASDAQ.
Where is Scinai Immunotherapeutics listed?
Scinai Immunotherapeutics Ltd. is listed on NASDAQ.
What is the SEC CIK of Scinai Immunotherapeutics?
The SEC Central Index Key (CIK) for Scinai Immunotherapeutics Ltd. is 1611747. Its filings are on SEC EDGAR.
How many shares does Scinai Immunotherapeutics have outstanding?
13,872,899,584 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-01.
Which country or territory is Scinai Immunotherapeutics listed under?
Our directory records Scinai Immunotherapeutics Ltd. under Israel.
What does Scinai Immunotherapeutics do?
Our directory classifies Scinai Immunotherapeutics Ltd. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline.
What is the ISIN of Scinai Immunotherapeutics?
The ISIN recorded for Scinai Immunotherapeutics Ltd. is US09073Q4029.
Does aibio.space cover Scinai Immunotherapeutics?
aibio.space lists Scinai Immunotherapeutics Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Scinai Immunotherapeutics incorporated?
SEC records list its state or country of incorporation as L3.
What was Scinai Immunotherapeutics's revenue last year?
$1.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Scinai Immunotherapeutics profitable?
Scinai Immunotherapeutics Ltd. reported a net loss of $8.3 million for the fiscal year ended Dec 31, 2025, and used $6.0 million of cash in operations, per its annual report to the SEC.
How much does Scinai Immunotherapeutics spend on research and development?
$2.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Scinai Immunotherapeutics have?
$1.7 million in cash at Dec 31, 2025, per its 20-F.
What is the latest Scinai Immunotherapeutics (SCNI) stock news?
Our latest story on Scinai Immunotherapeutics, dated Sep 21, 2026: "Scinai Immunotherapeutics regains Nasdaq bid price compliance". Nasdaq's September 18, 2026 letter says the ADSs closed at $1.00 or more for 19 consecutive business days. The matter is closed. Source.
Investor discussion: Scinai Immunotherapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
- Distress
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 6-K. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
- Financings
Reported a financing. SEC Form 6-K. Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 20-F. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Stock chart
SEC filings and registration
- SEC name
- Scinai Immunotherapeutics Ltd.
- CIK
- 1611747
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- SCNI (Nasdaq)
- State or country of incorporation
- L3
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer
- Business address
- JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM, Israel, 00000
- Phone
- 972-8-9302529
- Shares outstanding
- 13,872,899,584 as of 2025-12-31 (20-F filed 2026-04-01)
- Former names
- BiondVax Pharmaceuticals Ltd.
Recent filings
Listing details
- Company
- Scinai Immunotherapeutics Ltd.
- Ticker
- SCNI
- Listing
- NASDAQ
- Country or territory
- Israel
- Business scope
- Biopharma / pharmaceutical profile checked
- ISIN
- US09073Q4029
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction